Roth J, et al. - Researchers identified trends among pediatric neurosurgeons and oncologists with regard to incidental pediatric brain tumors (IPBT) management and approval of growth hormone replacement therapy (GHRT). One hundred forty-three responses were qualified for this investigation (92 neurosurgeons, 51 oncologists, from a total of 6 continents). Findings suggested that management recommendations for IPBT differed among the responders and appear to be influenced by many factors. It was noted that stable lesions lead to a shift in management towards a “watch and wait” approach, on the other hand, in growing lesions responders tended towards a “biopsy” or “resection” approach. This highlighted the requirement for a better understanding of the natural course of incidental brain tumors in children and also assessing the potential risk for malignant transformation.